British medical technology company Moletest (Scotland) is calling for clinicians and service managers to consider assessing nomela, a professional rule-out screening test for melanoma.
The technology uses image analysis software delivered via a dedicated iPad. Moletest (Scotland) aims to assess the clinical and technical usability of nomela in the real-world setting.
Clinicians and service managers in the community will now have the opportunity to be the first to try out this cutting-edge skin cancer screening technology while playing a crucial role in shaping its usability in practice. While ongoing clinical trials in secondary care aim to confirm accuracy in ruling out melanoma, practical insight on the device gathered from the usability assessment will provide evidence on nomela’s acceptability in a real-world setting and highlight any developments that can be made to address unmet needs.
Healthcare professionals taking part in the usability assessment will be trained to take images of skin lesions or moles suspected of melanoma using a dedicated nomela iPad. The images are then analysed against five algorithms to provide an instant result, either "No evidence of melanoma" or "Melanoma not excluded”. The test results can be viewed by clinicians and compared with their own analysis, but are not expected to influence the clinical decision.
